GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Walmsley confirmed that the company was interested in bidding for Pfizer’s consumer healthcare business, but refused to comment on whether paying out the necessary billions would hit GSK’s ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and ... it rejected a £50 billion approach from Unilever for its consumer health joint venture with Pfizer, which according to ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone needs almost every day. These stocks are able to sustain any economic ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...